Trial Profile
Phase II study of Alimta [pemetrexed] treatment of advanced thymoma and thymic carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 22 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 26 Oct 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.